Disease-Free Survival
OSI Pharmaceuticals Announces That "RADIANT", an International Phase III Tarceva Adjuvant Trial in Non-Small Cell Lung Cancer, Completes Enrollment
Published in Cancer Weekly, May 11th, 2010
OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva® (erlotinib) as an adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer (NSCLC) who have undergone surgery and have EGFR-positive tumors. RADIANT is an international, randomized, double-blinded, placebo-controlled Phase III study that has reached its enrollment goal of 945 patients. The primary objective of the study is to determine whether the targeted therapy Tarceva prolongs disease-free survival when given as an adjuvant therapy. This is defined as a cancer treatment that is given after the primary treatment,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2010-05-11)
More Articles from Cancer Weekly
- Bowel Cancer
Quick new screening exam could save thousands of people from bowel cancer - Lung Cancer
Lung Cancer Alliance Issues Statement on Recently Released Federal Study on Lung Cancer Screening - Quality of Life
Studies from Guangzhou Medical College, Department of Gastroenterology yield new data on quality of life - Nutrition
Study findings from National Institute for Public Health and the Environment broaden understanding of nutrition - Head and Neck Cancer
Research on head and neck cancer reported by scientists at Chang Gung Memorial Hospital - Prostate Cancer
Scientists at Kobe University describe research in prostate cancer - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
